In the final process of blood coagulation, fibrin molecules are stabilized via a catalytic reaction by Factor XIIIA (FXIIIA), a member of the transglutaminase (TGase) family that catalyzes protein cross-linking reactions. In this study, we characterized the orthologue of this enzyme in medaka (Oryzias latipes), an established model fish in which a coagulation system is also preserved. The recombinant protein of this orthologue enzyme was produced in baculovirus-infected insect cells and used for analysis of its biochemical properties including activation by thrombin proteolysis and calcium dependence of the TGase enzymatic activity. Immunostaining and immunoblotting revealed that medaka FXIIIA is expressed in the kidney, bone, and esophagus in addition to blood cells. Furthermore, a genemutant fish was established using the CRISPR/Cas9 system. The loss of FXIIIA expression was validated in the mutants, and phenotypes, such as absence of fibrin cross-linking, were investigated in the established mutant fish.
Introduction
Blood coagulation is an elaborate process that is essential during blood vessel injury. It involves the alteration of various functional molecules through several enzymatic reactions in a cascade manner. In this pathway, thrombin is as a key factor that proteolyzes fibrinogen to fibrin resulting in the assembly of fibrin for clot formation [1, 2] . In the final step, fibrin is crosslinked via covalent bonds and further stabilized. The resulting fibrin network is resistant to degradation and protected from the fibrinolytic enzyme. The cross-linking reaction is catalyzed by Factor XIII subunit A (FXIIIA), a member of the transglutaminase (TGase; EC 2.3.2.11) family [3, 4] .
TGase is an enzyme that catalyzes the formation of covalent isopeptide bonds between glutamine and lysine residues in a calcium ion-dependent manner [5] [6] [7] . This enzyme also catalyzes the incorporation of a primary amine instead of a lysine residue into the glutamine residue. In addition, a water molecule can be a substrate in the substitution of a glutamine residue into a glutamic acid residue, resulting in the addition of negative charges to the substrates. These post-translational modifications are essential for various biological phenomena in a wide variety of organisms from mammals to microorganisms. In mammals, the TGase enzyme family consists of eight isozymes: FXIIIA and TG1-TG7.
The FXIIIA isozyme is synthesized as a dimer in platelets and forms a tetramer with a Factor XIII subunit B (FXIIIB) dimer in the blood stream; this association is necessary to stabilize FXIIIA. Upon clot formation, FXIIIA dissociates from FXIIIB and is activated by thrombin via limited proteolysis, resulting in the cross-linking of fibrin molecules. Hence, the loss of FXIIIA activity by genetic mutation causes several diseases mainly related to clotting deficiencies [8, 9] . In addition, this enzyme, expressing in osteoblasts and chondrocytes, is also involved in bone formation [10] [11] [12] . Although the biological functions of the enzyme in blood clotting have been extensively investigated and specific inhibitors have been developed [13, 14] , the pathological and physiological significance of FXIIIA activity are not completely clarified.
Medaka (Oryzias latipes), a model organism similar to zebrafish (Danio rerio), has been used recently for pathological and pharmaceutical studies including observation of symptoms, drug screening, and for studying a disease initiation mechanism [15] [16] [17] . This fish model presents several advantages for these studies owing to its high fertility, easy maintenance, and short generation time [18] [19] [20] . The model is also amenable to genetic modifications: gene-editing techniques such as transcription activation-like effector nuclease (TALEN) [18] and the CRISPR/Cas9 system are currently available [21] [22] [23] . These recent successes in establishing gene-deficient fish will further contribute to our basic scientific knowledge and stimulate application in preclinical science such as drug screening.
Recently, we identified all the medaka orthologues for mammalian TGases in the genome database and have characterized some enzymes biochemically [24, 25] . In this study, we present the biochemical analyses, enzymatic properties, and tissue distribution of the orthologue (medaka FXIIIA) for human FXIIIA. Moreover, we successfully established two different genetic allelic mutants carrying catalytically inactive medaka FXIIIA and investigated their phenotypes.
Results
Sequence of FXIIIA and its deduced primary structure As shown in Fig. 1A , the aligned amino acid sequences of human FXIII (HsFXIII) and medaka FXIIIA (OlFXIIIA), the medaka orthologue, demonstrate an identity of 48% and a similarity of 83%. These values show significant homology between the two genes, which is supported by phylogenetic tree analysis (Fig. 1B) . FXIIIA encodes 739 amino acids with a possible cleavage site by thrombin as shown in Figs 1 and 2B. The tertiary structure of the major mammalian TGases analyzed consists of four domains (b-sandwich, catalytic core, b-barrel 1, and b-barrel 2). Based on the sequence homology, medaka FXIIIA could adopt a similar structure. Additionally, possible calcium binding sites, which are preserved among the mammalian TGase isozymes, are found mostly (11 of 14 residues) in the medaka FXIIIA sequence.
We searched also the medaka orthologue of FXIII B subunit, which stabilizes the FXIII A subunit. Based on the cDNA sequence for mouse FXIIIB (NM_ 031164), a similar search for the orthologues was carried out using a cDNA database (NBRP) and also a genome database (Ensemble genome browser: http:// www.ensembl.org/index.html), but we found no meaningful orthologue in the medaka gene.
Biochemical analyses of the recombinant protein for FXIIIA
To characterize the biochemical properties of medaka FXIIIA that are different from those of the other orthologues, we produced a recombinant protein in a baculovirus-insect cell system since the bacterial system resulted in expression as insoluble protein probably due to incorrect folding (data not shown). The protein obtained using the baculovirus system was purified to homogeneity by metal ion affinity chromatography and size separation ( Fig. 2A) . Upon size separation, recombinant FXIIIA was eluted as the peak fraction approximately at the molecular size of 160 kDa, suggesting that medaka FXIIIA forms a dimer as in the case of human FXIIIA (data not shown).
Because mammalian FXIIIA is activated by limited proteolysis with thrombin, we examined whether the purified recombinant FXIIIA was cleaved in a similar manner. Digestion with human thrombin produced a proteolyzed form of the medaka orthologue at the molecular size deduced from the predicted cleavage site (Fig. 2B,C) . Then, we confirmed the TGase enzymatic activity by incorporation of 5-(biotinamido)pentylamine (BPA; biotin-labeled pentylamine), a glutamine donor , respectively. In both analyses, the data show the mean AE SD based on triplicate samples.
substrate, into b-casein as a lysine-donor substrate. When the nontreated and the thrombin-proteolyzed forms of FXIIIA were compared, the enzymatic activity was apparently enhanced with thrombin digestion (Fig. 2D ). The enzymatic reaction for the incorporation of BPA was time and calcium dependent (Fig. 3A) .
With the three different amounts of the activated enzyme, the reaction showed substrate concentration dependency (Fig. 3B ). These results suggest that the proteolyzed form of FXIIIA becomes an active TGase in a calcium ion-dependent manner, through thrombin digestion similar to mammalian FXIIIA.
Tissue distribution of FXIIIA analyzed by immunoblotting and immunostaining
Using an affinity-purified polyclonal antibody, the expression pattern of FXIIIA was analyzed by immunoblotting. No significant cross-reactivity with other medaka TGases was observed using each recombinant protein (data not shown).
Tissue extracts from wild-type fish were subjected to immunoblotting. As shown in Fig. 4 , expression of FXIIIA was observed in several tissues including gill, kidney, bone, and heart as well as in plasma clot. The molecular size was similar to that of its recombinant protein as a positive control at the precursor size. These results suggested that FXIIIA is expressed in the hematopoietic tissues, bone, and plasma mainly in the precursor form.
Furthermore, whole-tissue sections prepared in adult fish were reacted with the antibody in parallel with negative control and H&E staining (Fig. 5A ). Three areas showed significant signals: the pharyngeal cavity, vertebra, and the distal pterygiophore (Fig. 5B ). In the pharyngeal cavity, several upper layer cells were stained. Expression in vertebra and distal pterygiophore, as bone and cartilage, showed higher reactive signal pattern than the pharyngeal cavity.
Establishment of the medaka mutants for the FXIIIA gene by the CRISPR/Cas9 system
To obtain mutant fish harboring aberrant FXIIIA activity, we applied CRISPR/Cas9 gene-editing technology and generated gRNA targeting either exon 1 or Fig. 4 . Analysis of tissue distribution by immunoblotting. The extracts from several tissues of wild-type fish were subjected to 7.5% SDS/ PAGE following immunoblotting using affinity-purified polyclonal antibody against medaka FXIIIA. The similar amounts of the extracted proteins were loaded with recombinant FXIIIA (rFXIIIA) used as a positive control. Lanes: gill, kidney, spleen, bone, clot, eye, brain, intestine, liver, and heart. exon 3 of the gene, both of which are upstream of the DNA region encoding the active site residue (Cys) of the enzyme. For this approach, two appropriate target sites were found on chromosome 18, on which the FXIIIA gene is located, and were designed to introduce Cas9 nuclease attack.
The embryos were injected with gRNA along Cas9 mRNA by standard procedure, and these F0 founders were raised to adulthood. We outcrossed the F0 fish with wild-type fish, and analyzed their progeny (F1) by heteroduplex mobility assay (HMA) and sequence analyses around the target site. Among the F1 progeny, two different alleles were selected based on the resulting deletion and frame shift in primary structure. These heterozygotes were in-crossed and we successfully obtained homozygotes for each mutant, designated as FXIIIAdel7 and FXIIIAdel8 encoding 218 and 28 amino acid residues of FXIIIA, respectively (Fig. 6A) . In their primary sequences, after their respective positions at 28 and 8 amino acid residues from the C terminus, proteins were incorrectly translated by the frame shift. Both mutated FXIIIA proteins lacked the amino acid residues for the catalytic triad that is located after the early stop codon.
To test the expression level of FXIIIA in the genedeficient fish, immunoblotting was carried out on tissue extracts from both mutant fish, FXIIIAdel7 and FXIIIAdel8. Figure 6B shows expression of FXIIIA in kidney, bone, clot, and heart of the wild type, whereas no expression was observed as a complete form in the case of both mutants (Fig. 6B) .
Furthermore, possible thrombocytes of medaka were stained for anti-medaka FXIIIA using blood from wild type and mutant medaka. Medaka blood cells, mostly erythrocytes, were stained by May-Giemsa staining as a standard method for mammalian cells. Specific immunostaining was obtained in the wild type possible thrombocytes though we currently have specific medaka marker proteins in the cells. However, both mutants (FXIIIAdel7 and FXIIIAdel8) did not show any significant signal in the preparations. In Fig. 7 , the representative areas were shown among the treated cells.
Analysis of the phenotype of the mutant medaka
To know the pattern of fibrin as substrate for FXIIIA upon coagulation, the clot was analyzed by SDS/ PAGE and immunoblotting. From the blood in wild type and mutants, extract from the clot was prepared and subjected to pattern analysis. We attempted immunologically specific detection of medaka c-fibrin using polyclonal antibody against human fibrin (Fig. 8) . In the wild type, the dimerized c-fibrin by cross-linking was observed with a similar position to the dimerized human fibrin, but not as the monomeric form. In contrast, fibrin remained as a monomer in the case of both FXIIIA mutants, although a similar pattern was observed in the plasma. These results suggest that the FXIIIA-mutant fish carries an inactive coagulation enzyme resulting in absent fibrin crosslinking.
Discussion
The activated form of FXIIIA plays an important role in fibrin clot formation via cross-linking reactions, an essential step for initiating wound healing. FXIII, initially identified as a blood coagulation factor, has possibly other functional roles, and hence, unexpected diseases might be induced upon its aberrant activity. This enzyme is expressed also in bone and contributes to bone maturation via stabilization of the extracellular matrix. Thus, with regard to the expression of FXIIIA in the platelets and regulation of fibrin stabilization, several issues still remain to be resolved.
In this study, we used medaka as a model animal to investigate the physiological functions of FXIIIA. Medaka has been established as a suitable model particularly for drug screening and pathological analysis upon gene mutation or pharmaceutical treatment. After biochemical analyses of the recombinant protein of medaka FXIIIA, the orthologue for human FXIIIA, we established a gene-mutant fish and analyzed its phenotype. 8 . Clot analysis on the blood from the wild type and the mutant medaka fish. Each blood sample harvested from wild type (WT) and the mutants (del7; FXIIIAdel7, del8; FXIIIAdel8) was promoted for coagulation. The proteins extracted from the clot were subjected to 10% SDS/PAGE and to immunoblotting using antibody against human c-fibrinogen. As controls, nontreated human fibrinogen (3 ng), human FXIIIA-treated fibrin (3 ng), and plasma from each fish were also used. The closed and open arrowheads indicate monomer and dimerized c-fibrin, respectively. The asterisks are nonspecific binding proteins.
Structural and biochemical properties of medaka FXIIIA appeared quite similar to human FXIIIA in this study, in addition to the phylogenic tree analyzed for all the medaka orthologues and mammalian enzymes (Fig. 1B, [24] ). First, the primary sequences around the catalytic triad and calcium-binding region are highly homologous with mammalian FXIII. Based on sequence conservation, FXIIIA might consist of four domains commonly observed in all mammalian TGases. Second, FXIIIA is synthesized as a zymogen form and proteolyzed in a limited way for activation by thrombin. In this experiment, human thrombin was used for digestion, but we consider a similar proteolytic reaction may be responsible because a possible medaka orthologue to thrombin was found in the cDNA database (with 25% homology in the deduced primary sequence). Third, the transamidation enzymatic activity is present in a calcium ion-dependent manner (Fig. 3) .
Expression analyses indicate that FXIIIA is apparently expressed in platelets and in the kidney. In the gill and heart, lower expression was observed probably due to remains of the clot. Expression in bone and esophagus was additionally revealed by the immunohistochemical analysis. Studies in mammals reported that FXIII is expressed in osteoblasts, chondrocyte, and preadipocyte cells [10] [11] [12] , which is consistent with our present data. Our results support that FXIIIA plays multiple roles at several tissues including bone, while a recent report described that FXIIIA is not functionally expressed in bone [26] . Identification of substrates in these tissues and cells, by direct mass-spectrometry analysis of the cross-linking reaction products using labeled primary amine, could provide new clues.
We established medaka mutants with aberrant FXIIIA enzymatic activity using a gene-editing method, CRISPR/Cas9. Two target sites in the genome were successfully mutated, disrupting the translation of a functional enzyme. From a series of analyses, it was apparent that both mutants did not express functional FXIIIA. FXIII deficiency frequently leads to abortion upon pregnancy in mammals even if the symptom of bleeding is not heavy [8] . In our fish model, however, we observed the normal shape and viability upon propagation. In addition, the heterozygotes produced mutant offspring at a Mendelian ratio.
Although medaka fibrin has not been characterized, we validated it upon clot formation using polyclonal antibody against human c-fibrin. Expectedly, aberrant fibrin polymerization was observed in both mutants in the clot. As another finding, abnormal excrescence (osteophyte-like) structures were observed in the spine in both mutant fish as a reproducible observation (Fig. 9) . Currently, we have not clarified the cause of this phenotype, but it suggests that expression of FXIIIA in bone is necessary for spine development.
Aberrant expression levels of FXIIIA cause impairment in wound healing, cardiac pathology, obesity, and arthritis [27] [28] [29] [30] [31] . Conversely, reduction of FXIIIA has been observed in several medical conditions such as pulmonary embolism, stroke, and leukemia [8] . Based on these studies for human diseases, analysis of other phenotypes in mutant fish is ongoing. In this study, by biochemical and immunochemical data, we identified the orthologue for human FXIIIA. We also showed that this orthologue displays similar proteolytic activation and established gene-deficient fish. Further phenotypic analyses of our mutants could contribute to a better understanding of FXIII-related diseases and drug screening.
Experimental procedures

Ethics
Fish care and maintenance were carried out according to the Regulations for Animal Experiments in Nagoya University. Animal experiments in this study were approved by the Animal Care and Use Committee of Nagoya University.
Sequence analysis of medaka FXIIIA, orthologue of human FXIIIA
The vector plasmid harboring FXIIIA cDNA was obtained from NBRP (National BioResources Project Medaka, Okazaki, Japan): clone ID, olsp35n14. The nucleotide sequence for the open-reading frame of FXIIIA was analyzed, and the data were deposited at DNA DataBank of Japan (DDBJ) with accession no. LC068825 [24] . Alignment, calculation of identity and similarity, and depiction of the primary sequence were performed by the DNA analysis software GENETYX (Genetyx, Osaka, Japan).
The name of the gene was first designated as OlTGB [24, 25] , but to avoid confusion with the orthologue of the FXIII B subunit, we changed it to medaka FXIIIA.
Expression and purification of recombinant protein
Initially, the FXIIIA cDNA was inserted into the pET24dHis vector for expression in bacteria as described previously [24] . This expression was able to produce recombinant protein attaching with a hexahistidine tag at the N terminus. The constructed plasmid (pET24dHisOlFXIIIA) was used for transformation of BL21(DE3)pLysS, and inducible expression by isopropyl b-D-1-thiogalactopyranoside was performed.
Since the expression in bacteria resulted in insoluble protein upon expression, a baculovirus-insect cells system was used to obtain soluble protein. The FXIIIA cDNA attached with the hexahistidine-tag coding sequence was amplified from the pET24dHisOlFXIIIA and inserted into the baculovirus expression vector plasmid, pFastBac TM 1 (Bac-to-Bac Baculovirus expression system; Thermo Fisher Scientific, Waltham, MA, USA). For recombination to produce packaged virus, the constructed plasmid was introduced into DH10Bac. The insect cells, Sf9, were propagated for infection and the obtained recombinant virus was infected at a multiplicity of infection of 1-10.
For purification of the recombinant protein, total cellular proteins were extracted from the infected Sf9 cells by lysis with hypotonic buffer: 10 mM Tris/HCl pH 8.0, 1 mM b-mercaptoethanol and protease inhibitor cocktail (Merck Millipore, Darmstadt, Germany). Then, after sonication and addition of NaCl to a final concentration of 150 mM, the lysate was applied to the TALON gel (Clontech-TAKARA Bio, Kyoto, Japan) and eluted by Tris-buffered saline containing 150 mM imidazole. For further purification, the eluate fraction was size-fractionated by Superdex-200 increase (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).
Proteolytic activation and measurement of the enzymatic activity
The enzymatic activity of the recombinant protein was examined after limited digestion with human thrombin (R&D Systems, Minneapolis, MN, USA), which triggers mammalian FXIIIA zymogen for activation. One microgram of the recombinant medaka FXIIIA was digested by thrombin for 20 min at 37°C at a final concentration of 40 ngÁlL À1 . Limited proteolysis was confirmed by 7.5% SDS/PAGE, and then the products were subjected to the enzymatic assay.
For evaluation of the enzymatic activity, a microtiter plate assay was performed as described previously [24] . b-Casein was coated onto a 96-well plate and blocked with skim-milk to avoid nonspecific binding. For the proteolyzed FXIIIA followed by treatment with thrombininhibitor, biotin-pentylamine (BPA) (Pierce, Rockford, IL, USA) was mixed in a reaction buffer containing 40 mM Tris/HCl (pH 8.0), 5 mM CaCl 2 , 1 mM b-mercaptoethanol, and protease inhibitor. In the case of the reaction containing the chelator for calcium ions, EDTA was included at a final concentration of 15 mM. After washing, streptavidin-peroxidase solution (Rockland Immunochemicals Inc., Gilbertsville, PA, USA) was added to detect the biotin-conjugated complex. Then, color development was carried out using the peroxidase substrate 3,3 0 ,5,5 0 -tetramethylbenzidine (Rockland Immunochemicals Inc.).
Immunochemical analyses for tissue distribution of FXIIIA
Antibody was prepared using the purified recombinant protein for FXIIIA. Nine hundred micrograms of protein was used for immunization to rabbit and its serum was obtained. The serum was subjected to affinity purification using recombinant FXIIIA-immobilized gel. For immobilization, N-hydroxysuccinimide gel was mixed with the purified FXIIIA according to the standard method. The cross-reactivity of the affinity-purified polyclonal antibody was examined with the recombinant proteins for other medaka orthologues, prior to use for immunoblotting and immunohistochemical analyses (data not shown). For immunoblotting, the protein extracts were prepared from several tissues. Briefly, tissue was excised and homogenized in a lysis buffer containing 10 mM Tris/HCl (pH 8.0), 1 mM EDTA, 1 mM b-mercaptoethanol, and protein inhibitor cocktail. For preparation of clot extract, blood was coagulated at 25°C for 1.5 h. The clot extract was obtained by homogenization in a lysis buffer followed by sonication. Each supernatant after centrifugation (12 000 g, 5 min) was subjected to 7.5% SDS/PAGE and transferred onto the polyvinylidene difluoride membrane (Merck Millipore). The membrane, after being blocked by skim-milk, was reacted with the antibody at a concentration of 0.075 lgÁmL À1 overnight at 4°C. The membrane was subjected to peroxidase-conjugated secondary antibody and then developed using chemiluminescent reagent (Thermo Fisher Scientific). For immunohistochemical analysis, the fish was paraffinembedded after fixation with Davidson solution (acetic acid, formaldehyde, and ethanol). Then, 10-lm tissue serial sections of the fish were prepared according to the standard method. The sections were deparaffined and heat-treated. The immunohistochemical reaction was carried out using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's manual. After blocking by a buffer containing nonimmunized goat serum, the sections were reacted with the primary antibody against FXIIIA at 4°C overnight, and then with avidin and biotin-labeled secondary antibody in the kit. All the sections were finally treated by 3,3 0 -diaminobenzidine (DAB) for color development. Hematoxylin and eosin (H&E) staining was carried out in parallel after fixation by the standard method. The sections were observed under a fluorescence microscope (BZ-9000; Keyence, Osaka, Japan). Blood cells were harvested and fixed on the slide glass. May-Giemsa staining was simultaneously performed according to the standard method. For immunostaining, cells were fixed by 95% ethanol and subjected to primary antibody solution. The secondary antibody was reacted with cells followed by DAB staining.
Plasmids expressing Cas9 mRNA and gRNAs
For design of the gRNAs, E-CRISP (http://www.e-crisp.org/ E-CRISP/designcrispr.html) was used as a software tool to predict unique target sites throughout the medaka genome. Moreover, to find possible off-target sites, pattern match tool software (http:.//viewer.shigen.info/medakavw/crisprtool/) was used to avoid the false attack by gRNA. The target sequences from two areas in exon 1 (LG18932206-LG18932226; ACTCCCTCTAAGGGGAACAGG) and exon 3 (LG18937465-LG18937485; CCAGACAAAAGCCGAGA GATG) were selected as candidates as the final selected sequences to produce the efficient gRNAs (Fig. 6A) . Then, two sets of the oligonucleotides were designed: 5 0 -TAG GACTCTCTCGGCTTTTGTC-3 0 (sense) and 5 0 -AAACGA CAAAAGCCGAGAGATG-3 0 (antisense) for exon 3; 5 0 -TA GGACTCCCTCTAAGGGGAAC-3 0 (sense) and 5 0 -AAACG TTCCCCTTAGAGGGAGT-3 0 (antisense) for exon 1. They were annealed and inserted into BsmBI-digested pT7-gRNA vector (Addgene plasmid no. 46759, Cambridge, MA, USA) [32] . For RNA synthesis, the two constructed vector plasmids of pT7-gRNA containing gRNA sequences were digested by BamHI and purified. The linearized plasmid was used as a template for in vitro transcription with T7 RNA polymerase (Promega, Madison, WI, USA) to obtain each gRNA. For Cas9 mRNA production, pCS2hSpCas9 vector (Addgene plasmid no. 51815) [23] was linearized by NotI digestion and subjected as a template to capped RNA synthesis with mMessage mMachine SP6 Transcription Kit (Thermo Fisher Scientific). After digestion by DNase I, the reaction products were purified by phenol/chloroform extraction and ethanol precipitation.
Establishment of gene-mutated medaka by CRISPR/Cas9 system
The solution (approximately 0.5 nL) containing gRNA (50 ngÁlL À1 ) and Cas9 mRNA (150 ngÁlL À1 ) was injected into one to four cell stage embryos (OK-Cab strain) with a manipulator (Narishige, Tokyo, Japan). Genome DNA was extracted from randomly selected embryos for analysis of the efficiency in gene editing by heteroduplex mobility assay (HMA) as described below and also for DNA sequencing. The F0 fish, grown from the injected egg, was interbred with wild-type fish (OK-Cab strain) to produce F1 heterozygotes. Among the F1 fish, males and females that carry an identical mutation were mated (in-crossed) to obtain homozygous progeny and/or a mutant family line.
For detection of mutation in the genome, HMA was carried out as a standard method [33] . Briefly, genomic DNA was prepared from the embryo or an excised fin by dissolving in a solution containing 0.2 mM EDTA and 25 mM NaOH followed by neutralization with 40 mM Tris/HCl (pH 8.0). Using the solutions as a template, PCR was carried out using KOD-Plus NEO (Toyobo, Osaka, Japan) and the set of primers to amplify the target region covering the mutated sequences: for FXIIIAdel7, forward primer 5- cycles. The products of amplicon were separated on 12% PAGE so that their migration pattern could be compared.
